doi: 10.1038/srep29491
Factors to verify include solubility test results, stability data (pH 4.57.4), and proper storage conditions (28C, airtight, away from light)
These changes are unlikely to be clinically significant as all subjects had etravirine concentrations well above the median protein binding adjusted EC50 of 4 ng/mL (concentration to inhibit 50% of viral replication in vitro).15 Moreover, the reductions in etravirine concentration are comparable to those seen in clinical trials when etravirine was coadministered with darunavir/ritonavir.16 High rates of efficacy were described when etravirine 200 mg twice daily and darunavir/ritonavir were coadministered in patients with extensive resistance, despite a 30% decrease in etravirine pharmacokinetic parameters (compared with historical controls).17 In recent large randomized trials, twice-daily etravirine resulted in additional antiviral effect versus placebo despite the concomitant administration of a boosted protease inhibitor.18,19 Furthermore, in a pooled analysis of these trials, no association between etravirine pharmacokinetics and 48-week efficacy (viral load 90%
For example, contralateral breast cancer is the most common SPC that develops in patients diagnosed with a first breast cancer, accounting for approximately 50% of all SPCs 17
Although L-carnitine does not appear to cause significant side effects, high doses (5 or more grams per day) may cause diarrhea
